Now that the 5 year collaboration has just expired in April between Radient and Jaiva Technologies, we should be hearing soon concerning CIT.
Radient Pharmaceuticals Corporation (RPC), a US-based pharmaceutical company has entered into an exclusive 5-year collaboration agreement with Jaiva Technologies.
Under the terms of the agreement, Jaiva Technologies will collaborate with clinical laboratories, hospitals and physicians in India to conduct clinical trials for RPC’s Combination Immunogene Therapy (CIT) technology.
Jaiva will also support RPC in securing Indian government approval for the use of CIT as a cancer therapy and vaccine throughout the country.
“We are very excited to collaborate with Radient Pharmaceuticals on the further development and commercialization of CIT in India,”according to Dr. Umesh Bhatia, Jaiva CEO.
